KOS 1022

Known as: KOS-1022, KOS1022 
 
National Institutes of Health

Topic mentions per year

Topic mentions per year

2006-2012
01220062012

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2012
2012
PURPOSE We conducted a phase I dose-escalation study to define the maximum tolerated dose (MTD), pharmacokinetics (PK), and… (More)
  • table 2
  • table 1
  • table 3
  • figure 1
  • figure 2
Is this relevant?
2012
2012
Purpose: We conducted a phase I dose-escalation study to define the maximum tolerated dose (MTD), pharmacokinetics (PK), and… (More)
  • table 2
  • table 1
  • table 3
  • table 4
  • figure 1
Is this relevant?
2010
2010
Heat shock protein 90 (Hsp90) is a molecular chaperone with many oncogenic client proteins. The small-molecule Hsp90 inhibitor… (More)
  • table 1
  • table 2
  • figure 1
  • table 3
  • figure 2
Is this relevant?
2008
2008
BACKGROUND Alvespimycin (17-DMAG, KOS-1022), a potent small-molecule inhibitor of the protein chaperone Hsp90, is being developed… (More)
Is this relevant?
2006
2006
2081 Background: Disruption of Hsp90-client protein heterocomplexes leads to degradation of a variety of oncoproteins. KOS-1022… (More)
Is this relevant?